FibroBiologics Registers 22.5M Shares for Resale, Eyes $7.5M from Warrants

TL;DR

**FBLG's S-1 filing for 22.5 million warrant shares is a massive overhang, signaling potential dilution and a tough road ahead for a clinical-stage biotech.**

AI Summary

FibroBiologics, Inc. (FBLG) filed an S-1 to register the resale of up to 22,494,434 shares of common stock by selling stockholders, primarily stemming from recent private placements of warrants. The company will not receive any proceeds from these resales, but could receive up to approximately $7.5 million in aggregate gross proceeds if all warrants are exercised for cash. These warrants include 12,110,203 shares from November 19 Warrants with an exercise price of $0.3303, 4,477,614 shares from November 25 Warrants at $0.335, and 5,227,275 shares from December 16 Warrants at $0.33. Additionally, placement agent warrants for 313,433 shares at $0.4188 and 365,909 shares at $0.4125 were issued. All warrants are subject to stockholder approval for the underlying share issuance and have a five-year expiry from approval. The company is a clinical-stage biotechnology firm developing fibroblast-based therapies for conditions like wound healing and multiple sclerosis, with product candidates including CYWC628, CYPS317, CYMS101, and CybroCell™.

Why It Matters

This S-1 filing signals a potential significant increase in FBLG's public float, as up to 22,494,434 shares could enter the market from selling stockholders, potentially exerting downward pressure on the stock price, which closed at $0.2596 on December 22, 2025. For investors, the dilution risk is substantial, especially given the warrant exercise prices range from $0.33 to $0.4188, mostly above the current market price, making cash exercise less likely in the short term. The company's ability to secure up to $7.5 million from warrant exercises is crucial for funding its clinical-stage biotechnology pipeline, including therapies for multiple sclerosis and degenerative disc disease, in a highly competitive biotech landscape where capital is vital for R&D. Employees and customers will be watching to see if this capital infusion translates into accelerated product development and market success.

Risk Assessment

Risk Level: high — The risk level is high due to the substantial potential for dilution from the 22,494,434 shares registered for resale, representing a significant portion of the company's common stock. The last reported sales price of FBLG common stock was $0.2596 on December 22, 2025, which is below the exercise prices of most warrants (e.g., $0.3303, $0.335, $0.4188), making cash exercise less probable and increasing the likelihood of cashless exercise, which would not provide capital to the company.

Analyst Insight

Investors should exercise extreme caution and consider the significant dilution risk posed by the 22.5 million shares registered for resale. Given the current stock price of $0.2596 is below most warrant exercise prices, the potential for cash proceeds to the company is uncertain, and further price depreciation is a distinct possibility. Avoid FBLG until there is clear evidence of clinical success and a more stable capital structure.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• 22,494,434 — Shares of Common Stock (Maximum shares registered for resale by Selling Stockholders, indicating potential dilution.)
• $7.5M — Potential Gross Proceeds (Aggregate gross proceeds FibroBiologics could receive if all warrants are exercised for cash, crucial for funding operations.)
• $0.2596 — Last Reported Stock Price (Closing price on December 22, 2025, which is below most warrant exercise prices, impacting likelihood of cash exercise.)
• $0.3303 — November 19 Warrant Exercise Price (Exercise price for 12,110,203 shares, higher than current market price.)
• $0.335 — November 25 Warrant Exercise Price (Exercise price for 4,477,614 shares, higher than current market price.)
• $0.33 — December 16 Warrant Exercise Price (Exercise price for 5,227,275 shares, higher than current market price.)
• 5 years — Warrant Expiry Period (Duration after stockholder approval for which warrants remain exercisable.)
• 9.99% — Beneficial Ownership Cap (Maximum beneficial ownership for November 19 Warrant holders post-exercise.)
• 4.99% — Beneficial Ownership Cap (Maximum beneficial ownership for November 25 and December 16 Warrant holders post-exercise.)
• 3 — Private Placements (Number of recent private placements (November 18, November 24, December 14) that generated these warrants.)

Key Players & Entities

• FibroBiologics, Inc. (company) — Registrant and clinical-stage biotechnology company
• Pete O'Heeron (person) — Chief Executive Officer of FibroBiologics, Inc.
• Ruben A. Garcia (person) — General Counsel of FibroBiologics, Inc.
• H.C. Wainwright & Co., LLC (company) — Placement agent for November 24 SPA and December 14 SPA
• Securities and Exchange Commission (regulator) — Regulatory body for S-1 filing
• $7.5 million (dollar_amount) — Approximate aggregate gross proceeds upon full cash exercise of warrants
• $0.2596 (dollar_amount) — Last reported sales price of common stock on December 22, 2025
• 22,494,434 shares (dollar_amount) — Total shares of common stock registered for resale
• $0.3303 (dollar_amount) — Exercise price of November 19 Warrants
• $0.335 (dollar_amount) — Exercise price of November 25 Warrants

FAQ

Risk Factors

• Potential Dilution from Warrant Exercise [high — financial]: The S-1 filing registers up to 22,494,434 shares for resale by selling stockholders, primarily from exercised warrants. If all warrants are exercised, this could lead to significant dilution for existing shareholders. The company could receive up to approximately $7.5 million in gross proceeds if warrants are exercised for cash, but the current stock price of $0.2596 is below most exercise prices (ranging from $0.33 to $0.335), making cash exercise less likely.
• Stockholder Approval for Share Issuance [medium — regulatory]: All warrants are subject to stockholder approval for the issuance of the underlying shares. Failure to obtain this approval could prevent the exercise of these warrants and impact the company's ability to raise capital through warrant exercises. The five-year expiry period from approval adds a time-sensitive element to this risk.
• Clinical Stage Development Risks [high — operational]: As a clinical-stage biotechnology company, FibroBiologics faces inherent risks associated with drug development, including the lengthy and expensive process of clinical trials, potential for trial failures, and the need for regulatory approvals. Product candidates like CYWC628, CYPS317, CYMS101, and CybroCell™ are still in development, with no guarantee of commercial success.
• Dependence on Future Financing [high — financial]: The company's ability to fund its operations and development activities is dependent on future financing. While warrant exercises could provide up to $7.5 million, this is contingent on market conditions and stockholder approval. Significant cash burn is typical for biotech companies, increasing the risk of needing additional capital on potentially unfavorable terms.
• Competition in Regenerative Medicine [medium — market]: The field of regenerative medicine and therapies for wound healing and multiple sclerosis is competitive, with established players and emerging companies. FibroBiologics must demonstrate a clear therapeutic advantage and navigate a complex market landscape to achieve commercial viability.

Industry Context

FibroBiologics operates in the highly competitive and rapidly evolving regenerative medicine and biotechnology sector. The company focuses on fibroblast-based therapies for conditions like wound healing and multiple sclerosis. Key industry trends include advancements in cell and gene therapy, increasing investment in rare disease treatments, and a rigorous regulatory pathway for novel therapeutics.

Regulatory Implications

As a clinical-stage biotech, FibroBiologics is subject to stringent FDA regulations for drug development and approval. The success of its product candidates hinges on navigating complex clinical trial processes and demonstrating safety and efficacy. Stockholder approval for warrant issuance also introduces a regulatory hurdle that must be cleared.

What Investors Should Do

1. Monitor Stockholder Approval Status
2. Evaluate Dilution Impact
3. Assess Cash Burn and Funding Needs
4. Analyze Clinical Trial Progress

Key Dates

• 2023-11-19: Issuance of November 19 Warrants — These warrants represent a significant portion of the shares being registered for resale and have an exercise price of $0.3303.
• 2023-11-25: Issuance of November 25 Warrants — These warrants contribute to the total shares for resale with an exercise price of $0.335.
• 2023-12-16: Issuance of December 16 Warrants — These warrants add to the resale shares with an exercise price of $0.33.
• 2025-12-22: Last Reported Stock Price — The closing price of $0.2596 is below most warrant exercise prices, indicating a low likelihood of cash exercise for these warrants.

Glossary

S-1 Filing

A registration statement filed with the U.S. Securities and Exchange Commission (SEC) by companies planning to offer securities to the public. It contains detailed information about the company's business, financial condition, and the securities being offered. (This S-1 filing specifically registers the resale of shares by existing stockholders, not an offering of new shares by the company.)

Warrants

A type of security that gives the holder the right, but not the obligation, to buy a company's stock at a specified price (exercise price) before a certain expiration date. (The S-1 is driven by the resale of shares underlying these warrants, which were issued in recent private placements.)

Selling Stockholders

Existing shareholders who are registering their shares for resale to the public. The company does not receive proceeds from these sales. (The primary purpose of this S-1 is to allow these selling stockholders to liquidate their holdings derived from warrant exercises.)

Clinical-stage Biotechnology Company

A company focused on developing new drugs or therapies that are currently undergoing testing in clinical trials with human subjects. (FibroBiologics falls into this category, meaning its product candidates are not yet approved for commercial sale and face significant development risks.)

Beneficial Ownership Cap

A limit on the percentage of a company's voting stock that an individual or entity can own, often imposed by warrant agreements to comply with exchange listing rules or regulatory requirements. (These caps (9.99% and 4.99%) restrict how many shares warrant holders can exercise at once, potentially spreading out dilution over time.)

Year-Over-Year Comparison

This S-1 filing is primarily for the resale of shares by existing stockholders, stemming from recent warrant issuances. Unlike a typical S-1 for an initial public offering or a follow-on offering, FibroBiologics will not receive proceeds from these resales. The filing highlights potential future capital infusion of up to $7.5 million if warrants are exercised for cash, but the current stock price being below exercise prices suggests this is unlikely in the near term. No comparative financial metrics from a previous filing are directly presented in this context.

Key Financial Figures

• $0.00001 — 4 shares of our common stock, par value $0.00001 per share, or the common stock/Common S
• $0.3303 — ommon Stock and accompanying Warrant of $0.3303 with respect to the November 19 Warrant
• $0.335 — th respect to the November 19 Warrants, $0.335 with respect to the November 25 Warrant
• $0.33 — espect to the November 25 Warrants, and $0.33 with respect to the December 16 Warrant
• $0.4188 — on Stock, at an exercise price equal to $0.4188 per share, and for the Private Placemen
• $0.4125 — on Stock, at an exercise price equal to $0.4125 per share. The Warrants will be exercis
• $7.5 million — ver, we may receive up to approximately $7.5 million aggregate gross proceeds upon exercise
• $0.2596 — ted sales price of our common stock was $0.2596 per share. We are an “emerging
• $0.33029 — he price of each Pre-Funded Warrant was $0.33029 (equal to the price per share minus $0.
• $0 — 029 (equal to the price per share minus $0.00001, the exercise price of each Pre-F
• $4.0 million — itional gross proceeds of approximately $4.0 million. However, we cannot predict when or if
• $1.5 million — itional gross proceeds of approximately $1.5 million. However, we cannot predict when or if
• $1.7 million — itional gross proceeds of approximately $1.7 million. However, we cannot predict when or if
• $1.235 b — total annual gross revenue of at least $1.235 billion, (iii) the last day of the fiscal
• $700.0 million — Common Stock held by non-affiliates was $700.0 million or more as of the last business day of

Filing Documents

• forms-1.htm (S-1) — 501KB
• ex5-1.htm (EX-5.1) — 7KB
• ex23-2.htm (EX-23.2) — 5KB
• ex107.htm (EX-FILING FEES) — 24KB
• forms-1_001.jpg (GRAPHIC) — 5KB
• ex5-1_001.jpg (GRAPHIC) — 7KB
• 0001493152-25-029010.txt ( ) — 672KB
• ex107_htm.xml (XML) — 5KB

RISK FACTORS

RISK FACTORS 6 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 7 MARKET AND INDUSTRY DATA 8 TRADEMARKS, SERVICE MARKS AND TRADENAMES 8

USE OF PROCEEDS

USE OF PROCEEDS 9 DIVIDEND POLICY 9 PRINCIPAL AND SELLING STOCKHOLDERS 10 SHARES ELIGIBLE FOR FUTURE SALE 14 PLAN OF DISTRIBUTION 15 LEGAL MATTERS 16 EXPERTS 16 WHERE YOU CAN FIND ADDITIONAL INFORMATION 16 INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE 16 You should rely only on the information contained in this prospectus or contained in any free writing prospectus filed with the Securities and Exchange Commission. Neither we nor the Selling Stockholders have authorized anyone to provide any information different from, or in addition to, the information contained in this prospectus and in any free writing prospectuses we have prepared or that have been prepared on our behalf or to which we have referred you. Neither we nor the Selling Stockholders take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. The Selling Stockholders are offering to sell, and seeking offers to buy, shares of our common stock only under the circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date, regardless of the time of delivery of this prospectus or of any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since such date. For investors outside the United States: Neither we nor the Selling Stockholders have done anything that would permit the use of or possession or distribution of this prospectus or any related free writing prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock by the Selling Stockholders and the distribution of this prospectus outside the United States. ABOUT THIS PROSPECTUS

View Full Filing

View this S-1 filing on SEC EDGAR